Board of Directors

Jean-François Mouney co-founded GENFIT in 1999 after having been actively involved in the incubation of the Company from 1997. Prior to this, he had created, managed and developed several companies specializing in high-performance materials, particularly in the aeronautical industry, since 1979. In 1992, he founded M&M, a consultancy firm specializing in health economics. He was responsible for carrying out a feasibility study for an economic development agency within the field of health and biology in the Nord-Pas-de-Calais region of France and was appointed Chief Executive Officer of this agency since its launch in 1995. Over a hundred companies have been created as part of this venture, making Eurasanté one of the top European bioincubators and clusters. As Chairman of the Executive Board of GENFIT, he received, in 2003, the Entrepreneur of the Year award, which is organized internationally by Ernst & Young, in the New Technology category. He also received this award in 2004. Jean-François Mouney is also Deputy Chairman of the “Nutrition, Health and Longevity” research hub and is Advisor to the Banque de France since 2008. Jean-François Mouney is a graduate of the ESCP-Europe Business School, and holds a Master Degree in Economics from the University of Lille. Jean-François Mouney was GENFIT’s CEO for 20 years. He took on listing the company on the Nasdaq and lead GENFIT’s transformation from an innovative start-up to a biopharmaceutical company.

Mr. Eric Baclet has over 30 years of experience with Eli Lilly in international drug development, management, and commercialization, all expertise he gained as President and General Manager of Lilly Italia, General Manager of Lilly China, VP of Global Marketing, and Executive Directorship of International Marketing, to name a few. Throughout his tenure at Eli Lilly, Mr. Baclet spearheaded international drug launches across multiple geographies, and led multi-disciplinary teams involved in biopharmaceutical value-chain management in more than seven countries.

Since 2012, Dr. Catherine Larue has been CEO of the Integrated Biobank of Luxembourg (IBBL), where she leads the development of the biobanking strategy and new initiatives in the field of personalized medicine. During that time she acted for two years as CEO ad interim of the Luxembourg Institute of Health (LIH), the Luxembourg Biomedical Research Institute. Prior to joining the IBBL, Dr. Larue piloted the biomarker program at GENFIT until 2012. Dr. Catherine Larue began her career as an R&D team leader at Sanofi in the cardiovascular research department. She later joined Sanofi Diagnostics Pasteur in particular as Director, and then spent 11 years at the Bio-Rad group, holding different management positions. She participated in the discovery of several innovative biomarkers and the commercialization of dozens of diagnostic products. Dr. Catherine Larue holds a doctorate in experimental biology and an accreditation to direct research (Habilitation à Diriger la Recherche or HDR) from the University of Rouen, a degree in clinical oncology from the University of Paris VI and an executive MBA from St John’s University (New York).

Anne-Hélène Monsellato is a Certified Public Accountant in France since 2008 and graduated from EM Lyon in 1990 with a degree in Business Management. Since 2015, she has been an independent director, the Chairman of the Audit and Risk Committee and a member of the Corporate Governance and Nomination Committee of Euronav, a Belgian crude oil tanker company listed on NYSE and Euronext Brussels. In addition, she serves as the Vice President and Treasurer of the Mona Bismarck American Center for Art and Culture, a U.S. public foundation based in New York. From 2005 until 2013, Mrs. Monsellato served as a Partner with Ernst & Young (now EY), Paris, after having served as Auditor/Senior, Manager and Senior Manager for the firm starting in 1990. She has extensive experience in cross border listing transactions, in particular with the U.S., internal control and risk management, and was involved with several companies in the pharmaceutical and biotechnology sector. Mrs. Monsellato is an active member of the French Association of Directors (IFA) and of the selection committee of Femmes Business Angels since 2013.

Biotech Avenir Biotech Avenir SAS is a management holding company incorporated in 2001 by the Company's founders. Most of its share capital is currently held by individuals, i.e. the co-founders of the Company and twelve Company employees. Jean-François Mouney, the Chairman of the Board of Directors of the Company, is also the Chairman of the Management Committee of Biotech Avenir SAS. As of April 1, 2024, Biotech Avenir SAS held 3.79% of the share capital of the Company. Florence Séjourné Florence Séjourné, as member of the Management Committee of Biotech Avenir, represents Biotech Avenir in the Board of Directors of the Company. Florence Séjourné is the CEO of AUROBAC THERAPEUTICS, a biopharmaceutical company dedicated to the fight against severe bacterial infections and their consequences in acute hospital settings. Prior to this role, Florence served as CEO of DA VOLTERRA. She co-founded GENFIT with Jean-François Mouney and Pr. Bart Staels and spent 9 years working at GENFIT where she held the position of Chief Operating Officer. In 2008, she became a member of the Supervisory Board. In 2015, Florence founded the BEAM Alliance, an association representing over 70 European biotech companies developing innovative solutions against AMR where she is currently Board member. Florence holds engineering and pharmaceutical sciences degrees from Mines Paris - PSL and the University of Illinois at Chicago.

Ms. Kalin is currently a director on the boards of Clinical Genomics, a molecular diagnostic firm, Brown Advisory, a strategic advisory and investment firm, and Primari Analytics, a startup in artificial intelligence. From 2012-17, Ms. Kalin led corporate strategy at Celgene, a global biopharmaceutical company, for 5 1/2 years. Prior to that, Ms. Kalin held executive leadership roles in marketing, sales, strategy and new business development at Johnson & Johnson (J&J) from 2002 to 2011. Prior to J&J, Ms. Kalin served as a Partner at McKinsey and Company, a global management consulting firm, where she negotiated and led consulting assignments, as a strategic advisor to pharmaceutical, medical device and other healthcare companies

Jean-François Tiné is a seasoned senior investment banking executive. In 2017, he was appointed Chairman of Equity Capital Markets at Natixis Corporate & Investment Banking after joining Natixis in 2005 as Global Head of Equity Capital Markets. He began his career in various sales, trading and syndication positions in the London and Paris capital markets at Union Bancaire Privée, Crédit Suisse, First Boston and Bank of America. In 1993, he became an associate at MC Securities in London, before being appointed three years later as Global Head of Equity Syndicate at Société Générale in Paris.

Ipsen Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs. Ipsen has around 5,400 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). Sandra Silvestri, M.D., Ph.D., Sandra Silvestri represents Ipsen in the Board of Directors of the Company. Sandra Silvestri, M.D., Ph.D., joined Ipsen in 2023 as Executive Vice President, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs. Prior to joining Ipsen, Ms. Silvestri held multiple leadership roles at Sanofi and Eli Lilly in multiple disease areas including diabetology, endocrinology, neuroscience, immunology, dermatology, and oncology. Sandra Silvestri is a medical doctor specialized in endocrinology and metabolic diseases. She has been an investigator in several clinical studies, published numerous book chapters as well as scientific articles in international journals. She stays active as a professor at the medical schools of the University of Florence, Italy, and Descartes University in Paris.